For the fourth consecutive year, physicians ranked Pfizer reps as the pharmaceutical sales division that provides the most value to their practices.
According to Scott-Levin's annual survey, "Sales Force Structures & Strategies, 1998-1999," general and family practitioners, cardiologists, general surgeons and psychiatrists rated Pfizer above competitors. And, among the nine core specialty groups included in the survey, Pfizer came out on top.
Several factors helped tip the scales in Pfizer's favor in 1998, according the Newtown, PA-based consulting firm.
For one, the company launched Viagra for erectile dysfunction, a product that garnered widespread media and consumer interest. Physicians' need for information about the heavily requested drug effectively opened the door to sales reps with answers to their questions. Second, the company added Alta, its fifth sales force, for an additional 650 bodies in the field. The Alta force targeted primary care physicians.
Pfizer also launched Lipitor, a cholesterol reducer that the company copromotes with Parke-Davis, and developed a direct-to-consumer advertising campaign for Aricept, a product indicated for the treatment of Alzheimer's disease.
However, other sales forces earned the respect of certain customers, too.
Merck, for example, was rated number one by internal medicine specialists, nephrologists and endocrinologists. Glaxo Wellcome was rated best by pulmonologists and neurologists.
Wyeth-Ayerst, meanwhile, scored well with OB/GYNs and orthopedic surgeons, and Schering-Plough earned the nod from allergists and otorhinolaryngologists.
Gastroenterologists cited Astra Merck as their favorite, and pediatricians named Ross as their top pick in terms of salespeople. PR
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.